These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31300214)

  • 41. [A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].
    Wang X; Zhao Y; Chen Z
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):389-394. PubMed ID: 31196374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
    Yoshida T; Furuta H; Hida T
    Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The changing face of cancer treatments.
    Keohane D; Fitzgerald GP
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
    Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
    Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
    Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
    Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
    Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression.
    Takeshita M; Anai S; Mishima S; Inoue K
    Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982
    [No Abstract]   [Full Text] [Related]  

  • 52. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
    Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Gauvain C; Vauléon E; Chouaid C; Le Rhun E; Jabot L; Scherpereel A; Vinas F; Cortot AB; Monnet I
    Lung Cancer; 2018 Feb; 116():62-66. PubMed ID: 29413052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
    Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
    Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
    Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
    [No Abstract]   [Full Text] [Related]  

  • 60. Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Costantini A; Fallet V; Corny J; Friard S; Chouaid C; Duchemann B; Giroux-Leprieur E; Taillade L; Doucet L; Brosseau S; Wislez M; Tredaniel J; Cadranel J
    Lung Cancer; 2019 Apr; 130():128-134. PubMed ID: 30885333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.